Literature DB >> 34655417

Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications.

Chenyu Mao1, Yongfeng Ding2, Nong Xu3.   

Abstract

Prostate cancer (PCa) is one of the most common cancers in men and the cause of numerous cancer deaths in the world. Nowadays, based on diagnostic criteria, prostate-specific antigen (PSA) evaluation and rectal examination are used to diagnose prostate-related malignancies. However, due to the different types of PCa, there are several doubts about the diagnostic value of PSA. On the other hand, semen is considered an appropriate source and contains various biomarkers in non-invasive diagnosing several autoimmune disorders and malignancies. Evidence suggests that analysis of semen biomarkers could be helpful in PCa diagnosis. Therefore, due to the invasiveness of most diagnostic methods in PCa, the use of semen as a biologic sample containing various biomarkers can lead to the emergence of novel and non-invasive diagnostic approaches. This review summarized recent studies on the use of various seminal biomarkers for diagnosis, prognosis and prediction of PCa.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Prostate cancer; Semen

Mesh:

Substances:

Year:  2021        PMID: 34655417     DOI: 10.1007/s11010-021-04273-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  82 in total

Review 1.  Testosterone and prostate cancer: an historical perspective on a modern myth.

Authors:  Abraham Morgentaler
Journal:  Eur Urol       Date:  2006-07-27       Impact factor: 20.096

2.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Paul A Fearn; Michael W Kattan
Journal:  J Natl Cancer Inst       Date:  2006-05-17       Impact factor: 13.506

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

4.  Prostate Cancer, Version 1.2016.

Authors:  James L Mohler; Andrew J Armstrong; Robert R Bahnson; Anthony Victor D'Amico; Brian J Davis; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric M Horwitz; Michael Hurwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Richard J Lee; Joshua J Meeks; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ted A Skolarus; Eric J Small; Guru Sonpavde; Sandy Srinivas; Seth A Strope; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2016-01       Impact factor: 11.908

5.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Authors:  Andrew J Stephenson; Michael W Kattan; James A Eastham; Fernando J Bianco; Ofer Yossepowitch; Andrew J Vickers; Eric A Klein; David P Wood; Peter T Scardino
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

6.  The role of increasing detection in the rising incidence of prostate cancer.

Authors:  A L Potosky; B A Miller; P C Albertsen; B S Kramer
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 8.  The Diagnosis and Treatment of Prostate Cancer: A Review.

Authors:  Mark S Litwin; Hung-Jui Tan
Journal:  JAMA       Date:  2017-06-27       Impact factor: 56.272

9.  Tumor growth inhibition by mSTEAP peptide nanovaccine inducing augmented CD8+ T cell immune responses.

Authors:  Qiuqiang Chen; Ying Bao; Danielle Burner; Sharmeela Kaushal; Yu Zhang; Theresa Mendoza; Michael Bouvet; Cengiz Ozkan; Boris Minev; Wenxue Ma
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 5.671

Review 10.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.